Skip to search formSkip to main contentSkip to account menu

valganciclovir 450 MG Oral Tablet

Known as: VALGANCICLOVIR HCL 450MG TAB, valGANciclovir HCl 450 MG Oral Tablet, VALGANCICLOVIR HYDROCHLORIDE 450 mg ORAL TABLET, FILM COATED 
National Institutes of Health

Related topics

Related topics

31 relations
AIDS-Related Opportunistic InfectionsAnemiaCrospovidoneCytomegalovirus Infections

Broader (1)

Antiviral Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Clinical Characteristics of Cytomegalovirus (CMV) Infection After Universal Valganciclovir Prophylaxis in Pediatric Renal Transplant Recipients
Review
2015
Review
2015
Bone marrow suppression and associated consequences in patients after heart transplantation: A 6-year retrospective review.
AIMS To evaluate the incidence of bone marrow suppression and consequences of MMF dose adjustment in patients within the first… 
2015
2015
Everolimus and Valganciclovir Prophylaxis: How to Chase CMV But Not the Patient: Insights From PROTECT Randomized Study
2014
2014
Trichodysplasie spinulosique : efficacité d’un traitement par valganciclovir☆
2014
2014
Konnatale CMV-Infektionen
Zusammenfassung Während effektive Präventionsstrategien zu einem deutlichen Rückgang der meisten vertikalen Infektionen geführt… 
2012
2012
400 Ganciclovir-Resistant (GCV-R) CMV Is Common among Lung Transplant Recipients (LTR) Receiving Alemtuzumab Induction and Valganciclovir Prophylaxis (VGC px), and Treatment with Foscarnet (FOS) Is…
2012
2012
697 Extended Valganciclovir Prophylaxis (VGC px) Decreases CMV Disease in D+/R− Lung Transplant Recipients (LTR), but Is Limited by Late Onset Infections, Toxicity and Resistance
2009
2009
Valganciclovir-Sirup zur oralen Therapie symptomatischer konnataler und postnataler Cytomegalovirus-Infektionen – Zwei Fallberichte
2007
2007
Drug-resistant Cytomegalovirus in the Era of Valganciclovir Prophylaxis: Treatment and Outcome
2006
2006
Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post–liver transplant recipients
We read the article by Park et al. with great interest. The authors retrospectively studied the efficacy of low-dose oral… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)